AtriCure Announces Initiation Of The ABLATE Pivotal Trial To Evaluate The Isolator Synergy(TM) Bipolar Ablation System To Treat Atrial Fibrillation

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, announced that the first patient was successfully treated in AtriCure’s ABLATE clinical trial. Dr. Richard Kaplon, a well-known cardiac surgeon, performed the procedure at Mercy General Hospital in Sacramento, California.

More: continued here

Filed under: Cardiovascular on February 12th, 2008